RESUMO
Objective To investigate the effect of atovastatin combined with trimetazidine on cardiac function and inflammatory cytokines in patients with chronic heart failure(CHF). Methods Ninety-seven patients with CHF were randomly divided into three groups:control group treated with conventional therapy,atovastatin group treated with atovastatin based on conventional therapy, and combined treatment group treated with atovastatin and trimetazidine based on conventional therapy. The parameters of cardiac function, including left ventricular ejection fraction ( LVEF) and left ventficular end-diastolic diameter (LVEDD) ,and the plasma levels of CRP,brain natriuretic peptide(BNP) ,and TNF-α were detected in all patients of each group before and after treatment. Results The plasma levels of CRP,BNP and TNF-α in patients with cardiac function Ⅳ were significantly higher than in those with cardiac function ≤ Ⅲ (P<0. 05). There was significant difference in plasma levels of CRP, BNP,TNF-α,LVEF and LVEDD before and after treatment in all groups(P<0. 05 or P<0. 01). As compared with control group after treatment,the plasma levels of CRP,BNP and TNF-α after treatment in both atovastatin group and combined treatment group were decreased markedly(P<0. 05),so did LVEF, LVEDD and 6-min walk test(P<0. 05). There was no significant difference in changes of CRP,BNP and TNF-α plasma levels,LVEF and LVEDD between atovastatin group and combined group after treatment (P>0. 05),but 6-min walk test lengthened statistically in combined treatment group (P<0. 05). Conclusion Atovastatin based on conventional therapy may play a role in anti-inflammation by lowering the plasma levels of CRP, BNP and TNF-α in patients with CHF, thereby improving cardiac function. Atovastatin combined with tremetazidine could reduce the cardiac muscular oxygen consumption and raise the excise endurance in patients with CHF.
RESUMO
Objective To explore the relations between UA and serum hs-CRP, the effects of early intervention with atovastatin on serum hs-CRP in patients with UA and its clinical significance in the early management of UA. Methods T 60 patients with UA (UA group),53 patients with stable angina (SA group) and 50 healthy controls (control group) were enrolled to the study. The serum hs-CRP levels were measured by particle enhanced immunoturbidimetric assay. UA group were randomly assigned to the atovastatin group and the routine group for a 4-week treatment immediately after admission. Selected coronary artery angiography was performed in 78 patients and 29 healthy controls with Judkin's technique. Results Baseline of hs-CRP in patients with UA was significantly higher than those in SA group and control group ( P